BOFA Securities: Reiterates "Buy" Rating on JD Health (06618.HK) with a more positive outlook on the company's prospects.

According to the Wise Wealth APP, Bank of America Securities has released a research report stating that it has reiterated a "buy" rating on JD Health (06618.HK), optimistic about the company's high growth momentum and AI application potential; it is expected that by 2026, revenue and adjusted operating profit will increase by 15% and 26% respectively, higher than Ali Health's (00241.HK) 10% and 22%.